At the last check on Thursday, ADMA Biologics Inc.’s (NASDAQ:ADMA) stock was up $0.03, moving up 0.70 percent to $3.58. The average number of shares traded per day over the past five days has been 2,101,385 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.19 fall in that time frame. In the last twenty days, the average volume was 2,017,031, while in the previous 50 days, it was 2,285,458.
Since last month, ADMA stock retreated -7.62%. Shares of the company fell to $3.50 on 09/21/23, the lowest level in the past month. A 52-week high of $4.65 was reached on 08/15/23 after having rallying from a 52-week low of $2.24. Since the beginning of this year, ADMA’s stock price has dropped by -7.86% or -$0.29, and marked a new high 6 times. However, the stock has declined by -23.12% since its 52-week high.
ADMA stock investors should be aware that ADMA Biologics Inc. (ADMA) stock had its last reported insider trading activity 22 days ago on Aug 30. Grossman Jerrold B, the Director of the company, purchased of 130,000 shares for $3.71 on Aug 30. It resulted in a $482,144 investment by the insider. KWON YOUNG added 25,000 shares at an average price of $3.90 on Aug 24. The insider now owns 277,401 shares following the transaction. On Aug 22, Director Fong Bryant sold 1,433,304 shares at $3.87 apiece. The transaction was valued at $5,544,737.
Valuation Metrics
The stock’s beta is 0.82. Besides these, the trailing price-to-sales (P/S) ratio of 3.92, the price-to-book (PB) ratio of 5.42.
Financial Health
In the three months ended June 29, ADMA Biologics Inc.’s quick ratio stood at 2.50, while its current ratio was 6.30, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.96, and the total debt-to-equity ratio was 0.96. On the profitability front, the trailing twelve-month gross margin is 27.40% percent. In the year ended June 29, EBITDA margin amounted to -21.07%, whereas operating margins totaled -8.00%. Based on annual data, ADMA earned $35.27 million in gross profit and brought in $154.08 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -15.60%. Return on equity (ROE) for the past 12 months was -29.60%.
In ADMA Biologics Inc.’s quarter-end financial report for June 29, it reported total debt of $140.31 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ADMA’s revenue rose 43.19% to $56.91 million during the quarter, while net income inched up to $59.69 million. While analysts expected ADMA Biologics Inc. to report -$0.02 quarterly earnings, the actual figure was -$0.03 per share. During the quarter, the company generated $2.28 million in EBITDA. The liabilities of ADMA Biologics Inc. were 196.26 million at the end of its most recent quarter ended June 29, and its total debt was $151.51 million. The value of shareholders’ equity is $224.91 million.
Technical Picture
This quick technical analysis looks at ADMA Biologics Inc.’s (ADMA) price momentum. With a historical volatility rate of 17.85%, the RSI 9-day stood at 31.80% on 20 September.
With respect to its five-day moving average, the current ADMA Biologics Inc. price is down by -5.03% percent or -$0.19. At present, ADMA shares trade -10.25% below its 20-day simple moving average and +7.16% percent above its 100-day simple moving average. However, the stock is currently trading approximately +3.46% above its SMA50 and +6.85% above its SMA200.
Stochastic coefficient K was 11.11% and Stochastic coefficient D was 13.24%, while ATR was 0.14. Given the Stochastic reading of 17.31% for the 14-day period, the RSI (14) reading has been calculated as 36.98%. As of today, the MACD Oscillator reading stands at -0.11, while the 14-day reading stands at -0.18.
Analyst Ratings
ADMA Biologics Inc. (ADMA) has been rated Buy by analysts. According to 0 brokerage firms, ADMA is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate ADMA Biologics Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $6.00, the current consensus forecast for the stock is $5.00 – $7.00. Based on these forecasts, analysts predict ADMA Biologics Inc. (ADMA) will achieve an average price target of $6.00.
